Retrieve Medical (RMHI) 10-Q 19 Dec 22 2018 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Mar. 31, 2019	Dec. 16, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2018
Current Fiscal Year End Date	--09-30
Entity File Number	005-87668
Entity Registrant Name	PEAK PHARMACEUTICALS, INC.
Entity Central Index Key	0001452804
Entity Incorporation, State or Country Code	NV
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		78,363,567

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Current Assets
Cash	$ 587	$ 2,270
Total current assets	587	2,270
Total Assets	587	2,270
Current liabilities:
Accounts payable (including $86,913 and $85,062 due to related parties)	154,219	153,176
Accrued liabilities	10,956	7,186
Convertible notes payable	20,000	20,000
Notes payable	43,000	43,000
Total current liabilities	228,175	223,362
Total Liabilities	228,175	223,362
Stockholders' Deficit
Preferred stock, $0.0001 par value, 25,000,000 authorized, none issued or outstanding
Common stock, $0.0001 par value, 300,000,000 shares authorized, 78,363,567 shares issued and outstanding	7,836	7,836
Additional paid in capital	4,855,566	4,855,566
Accumulated deficit	(5,090,990)	(5,084,494)
Total Stockholders' Deficit	(227,588)	(221,092)
Total Liabilities and Stockholders' Deficit	$ 587	$ 2,270

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Statement of Financial Position [Abstract]
Accounts Payable, Related Parties, Current	$ 86,913	$ 85,062
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ .0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	78,363,567	78,363,567
Common stock, shares outstanding	78,363,567	78,363,567

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Operating expenses:
General and administrative (including fees paid to related party of $455 and $4,229, and $1,253 and $10,029, for the three and six months ended March 31, 2019 and 2018, respectively)	$ 1,773	$ 8,185	$ 2,726	$ 15,210
Total operating expenses	1,773	8,185	2,726	15,210
Operating loss	(1,773)	(8,185)	(2,726)	(15,210)
Other expenses:
Interest expense	(1,864)	(1,204)	(3,770)	(1,808)
Total other expenses	(1,864)	(1,204)	(3,770)	(1,808)
Net loss	$ (3,637)	$ (9,389)	$ (6,496)	$ (17,018)
Per share information:
Weighted average shares outstanding - basic and diluted	78,363,567	78,363,567	78,363,567	78,363,567
Net loss per share - basic and diluted	$ 0	$ 0	$ 0	$ 0

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Related Party, General and Administrative Expenses	$ 455	$ 4,229	$ 1,253	$ 10,029

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Sep. 30, 2017	$ 7,836	$ 4,855,566	$ (5,056,087)	$ (192,685)
Beginning Balance, Shares at Sep. 30, 2017	78,363,562
Net income			(7,629)	(7,629)
Ending Balance, Amount at Dec. 31, 2017	$ 7,836	4,855,566	(5,063,716)	(200,314)
Ending Balance, Shares at Dec. 31, 2017	78,363,562
Beginning Balance, Amount at Sep. 30, 2017	$ 7,836	4,855,566	(5,056,087)	(192,685)
Beginning Balance, Shares at Sep. 30, 2017	78,363,562
Net income				(17,018)
Ending Balance, Amount at Mar. 31, 2018	$ 7,836	4,855,566	(5,073,105)	(209,703)
Ending Balance, Shares at Mar. 31, 2018	78,363,562
Beginning Balance, Amount at Dec. 31, 2017	$ 7,836	4,855,566	(5,063,716)	(200,314)
Beginning Balance, Shares at Dec. 31, 2017	78,363,562
Net income			(9,389)	(9,389)
Ending Balance, Amount at Mar. 31, 2018	$ 7,836	4,855,566	(5,073,105)	(209,703)
Ending Balance, Shares at Mar. 31, 2018	78,363,562
Beginning Balance, Amount at Sep. 30, 2018	$ 7,836	4,855,566	(5,084,494)	(221,092)
Beginning Balance, Shares at Sep. 30, 2018	78,363,567
Net income			(2,859)	(2,859)
Ending Balance, Amount at Dec. 31, 2018	$ 7,836	4,855,566	(5,087,353)	(223,951)
Ending Balance, Shares at Dec. 31, 2018	78,363,567
Beginning Balance, Amount at Sep. 30, 2018	$ 7,836	4,855,566	(5,084,494)	(221,092)
Beginning Balance, Shares at Sep. 30, 2018	78,363,567
Net income				(6,496)
Ending Balance, Amount at Mar. 31, 2019	$ 7,836	4,855,566	(5,090,990)	(227,588)
Ending Balance, Shares at Mar. 31, 2019	78,363,567
Beginning Balance, Amount at Dec. 31, 2018	$ 7,836	4,855,566	(5,087,353)	(223,951)
Beginning Balance, Shares at Dec. 31, 2018	78,363,567
Net income			(3,637)	(3,637)
Ending Balance, Amount at Mar. 31, 2019	$ 7,836	$ 4,855,566	$ (5,090,990)	$ (227,588)
Ending Balance, Shares at Mar. 31, 2019	78,363,567

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net income (loss)	$ (6,496)	$ (17,018)
Change in operating assets and liabilities:
Accounts payable	(808)	864
Accounts payable - related parties	1,851	(10,204)
Accrued liabilities	3,770	4,809
Net cash used in operating activities	(1,683)	(21,549)
Cash flows from financing activities:
Proceeds from issuance of convertible notes payable		23,000
Net cash provided by financing activities		23,000
Net change in cash	(1,683)	1,451
Cash, beginning of period	2,270	2,991
Cash, end of period	587	4,442
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for income taxes

NATURE OF OPERATIONS, BASIS OF

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Mar. 31, 2019
Nature Of Operations Basis Of Presentation And Summary Of Significant Accounting Policies
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company was incorporated in Nevada on December 18, 2007. After a number of name changes, we again, changed our name to Peak Pharmaceuticals, Inc. on December 23, 2014. This name was consistent with our business operations and plans relating to development, manufacturing and marketing of hemp-based nutraceutical and supplement products for the human and animal health markets. On October 1, 2015, we discontinued certain operations of the Company. The Company is currently a “shell company” (as such term is defined in Rule 12b-2 under the Exchange Act). Throughout this report, the terms “our,” “we,” “us,” and the “Company” refer to Peak Pharmaceuticals, Inc. and its wholly-owned subsidiary, Peak BioPharma Corp. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial statements, instructions to Form 10-Q, and Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in our annual report on Form 10-K for the year ended September 30, 2018. In management’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation to make our financial statements not misleading have been included. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year, or any other period. Basis of Consolidation The unaudited condensed consolidated financial statements include the financial statements of the Company and our wholly owned subsidiary Peak BioPharma Corp. All inter-company balances and transactions among the companies have been eliminated upon consolidation. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made in connection with the accompanying consolidated financial statements include the valuation allowances against net deferred tax assets and accounting for convertible debt. Loss Per Share We calculate net loss per share in accordance with ASC Topic 260, Earnings per Share As of March 31, 2019 and September 30, 2018, the Company had two convertible notes with principal and accrued interest balances totaling $24,844 and $23,648, respectively. The note holders are entitled, at their option, to convert all or a part of their options at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. These common stock equivalents of approximately 334,050, and 317,009 shares as of March 31, 2019 and 2018, respectively, are not included in the calculation of diluted EPS as their effect would be anti-dilutive. As of March 31, 2019 and September 30, 2018, the Company had 3,291,000 in stock options outstanding which are exercisable at the holders’ option, with an exercise price of $0.0067, which are not included in the calculation of diluted EPS as their effect would be anti-dilutive. Recently Issued Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement In May 2014, the FASB issued ASU, 2014-09— Revenue from Contracts with Customers (Topic 606) In February 2016, the FASB issued ASU No. 2016-02, Leases, In April 2016, the FASB issued ASU 2016 – 10 “ Revenue from Contracts with Customers: identifying Performance Obligations and Licensing In August 2016, the FASB issued ASU 2016-15, “ Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments U In January 2017, FASB issued ASU 2017-01, “ Business Combinations (Topic 805) Clarifying the Definition of a Business On May 10, 2017, the Financial Accounting Standards Board (“FASB”) issued an Accounting Standards Update (“ASU”) 2017-09 “ Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting

GOING CONCERN AND MANAGEMENT'S

GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	6 Months Ended
	Mar. 31, 2019
Going Concern And Managements Liquidity Plans
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS As of March 31, 2019, the Company had an accumulated deficit of $5,090,990 and a working capital deficiency of $227,588. During the six months ended March 31, 2019, the Company incurred a net loss of $6,496 and used cash in operating activities of $1,683. As of March 31, 2019, the Company had cash of $587. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company recognizes it will need to raise additional capital in order to fund operations and meet its payment obligations. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will generate revenues, become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds on favorable terms, it will have to develop and implement a plan to further extend payables and to raise capital through the issuance of debt or equity on less favorable terms until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. Accordingly, the accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the unaudited condensed consolidated financial statements do not necessarily represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Mar. 31, 2019
Related Party Transactions
RELATED PARTY TRANSACTIONS	NOTE 3 – RELATED PARTY TRANSACTIONS Parties, which can be corporations or individuals, are considered to be related if they have the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence. Accounts payable – related parties are amounts payable to current and former officers and directors for services provided to the Company totaling $86,913 and $85,062, as of March 31, 2019 and September 30, 2018, respectively. These amounts include accounts payable to an entity controlled by our sole officer and director for financial services such entity is incurring on behalf of the Company totaling $12,036 and $10,185, as of March 31, 2019 and September 30, 2018, respectively. Total expense incurred related to this entity was $455 and $4,229 for the three months ended March 31, 2019 and 2018, respectively, and $1,253 and $10,029, for the six months ended March 31, 2019 and 2018, respectively, with no other related party expenses incurred.

CONVERTIBLE NOTES PAYABLE AND N

CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE	6 Months Ended
	Mar. 31, 2019
Convertible Notes Payable And Notes Payable
CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE	NOTE 4 – CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE, Convertible Notes Payable Loan with Trius Holdings Limited On March 17, 2017, the Company entered into an agreement with Trius Holdings Limited (“Trius”). Pursuant to the terms of the agreement, Trius acquired a 12% convertible note with an aggregate face value of $10,000. The note matures in one year and is unsecured. Trius is entitled, at its option, to convert all or a part of the principal outstanding at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. On May 11, 2018, the agreement had been amended to extend the maturing date of the note from March 21, 2018 to March 21, 2019. As of March 31, 2019 and September 30, 2018, the total accrued interest owing under this note was $2,441 and $1,843, respectively. As of the date of this report, that date has not been extended, and the Company is accruing interest at the default interest rate of 15%. Loan with Individual On March 30, 2017, the Company entered into an agreement with an individual. Pursuant to the terms of the agreement, the individual acquired a 12% convertible note with an aggregate face value of $10,000. The note matures in one year and is unsecured. The individual is entitled, at its option, to convert all or a part of the principal outstanding at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. On May 11, 2018, the agreement had been amended to extend the maturing date of the note from March 30, 2018 to March 30, 2019. As of March 31, 2019 and September 30, 2018, the total accrued interest owing under this note was $2,403 and $1,805 respectively. Subsequent to March 31, 2019, on December 3, 2021, the Company repaid this loan and accrued interest in full. Notes Payable Loan with Mediapark Investments Limited On January 10, 2018, the Company entered into an agreement with Mediapark Investments Limited (“Mediapark”.) Pursuant to the terms of the agreement, Mediapark acquired a 12% promissory note with an aggregate face value of $23,000. The note matures in 180 days on July 10, 2018 and is unsecured. As of July 9, 2018, the loan was extended to July 10, 2019. As of March 31, 2019 and September 30, 2018, the total accrued interest owing under this note was $3,365 and $1,989, respectively. As of the date of this report, that date has not been extended, and the Company is accruing interest at the default interest rate of 15%. Loan with Individual On April 2, 2018, the Company entered into an agreement with an individual. Pursuant to the terms of the agreement, we received a promissory note in the amount of $20,000. The note is unsecured, is due and payable in full on October 2, 2018, and it accrues interest at a rate of 12% per annum. As of the March 31, 2019 and September 30, 2018, the total accrued interest owing under this note was $2,387 and $1,190, respectively. Subsequent to March 31, 2019, on December 3, 2021, the Company repaid this loan and accrued interest in full.

STOCK OPTIONS

STOCK OPTIONS	6 Months Ended
	Mar. 31, 2019
Stock Options
STOCK OPTIONS	NOTE 5 – OPTIONS No stock options were granted during the six months ended March 31, 2019 and 2018. The following is a summary of outstanding stock options issued to employees and directors as of March 31, 2019 and September 30, 2018: Number Exercise Price per Average Outstanding March 31, 2019 and September 30, 2018 2,916,000 $ 0.0067 4.95 Exercisable, March 31, 2019 and September 30, 2018 2,916,000 $ 0.0067 4.95 The following is a summary of outstanding stock options issued to non-employees, excluding directors, as of March 31, 2019 and September 30, 2018: Number Exercise Price per Average Outstanding March 31, 2019 and September 30, 2018 375,000 $ 0.0067 4.54 Exercisable, March 31, 2019 and September 30, 2018 375,000 $ 0.0067 4.54 There was no equity-based compensation for the six months ended March 31, 2019 and 2018.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Mar. 31, 2019
Subsequent Events
SUBSEQUENT EVENTS	NOTE 6 – SUBSEQUENT EVENTS Issuance of Loans Payable During the year ended September 30, 2021, the Company received an aggregate of $275,000 related to the issuance of 14 notes payable to various noteholders, including an aggregate of $35,000 as a result of two notes payable issued to the Company’s Chief Executive Officer, a related party. The notes are unsecured, bear interest at 1.5% per annum, and mature on September 30, 2021. To date, the Company has made principal and accrued interest payment of $65,000 and $14,191, respectively. As of the date of this report, the original due date of such notes has not been extended and are in default.

NATURE OF OPERATIONS, BASIS O_2

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Mar. 31, 2019
Disclosure Nature Of Operations Basis Of Presentation And Summary Of Significant Accounting Policies Policies Abstract
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial statements, instructions to Form 10-Q, and Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in our annual report on Form 10-K for the year ended September 30, 2018. In management’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation to make our financial statements not misleading have been included. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year, or any other period.
Basis of Consolidation	Basis of Consolidation The unaudited condensed consolidated financial statements include the financial statements of the Company and our wholly owned subsidiary Peak BioPharma Corp. All inter-company balances and transactions among the companies have been eliminated upon consolidation.
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made in connection with the accompanying consolidated financial statements include the valuation allowances against net deferred tax assets and accounting for convertible debt.
Loss Per Share	Loss Per Share We calculate net loss per share in accordance with ASC Topic 260, Earnings per Share As of March 31, 2019 and September 30, 2018, the Company had two convertible notes with principal and accrued interest balances totaling $24,844 and $23,648, respectively. The note holders are entitled, at their option, to convert all or a part of their options at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. These common stock equivalents of approximately 334,050, and 317,009 shares as of March 31, 2019 and 2018, respectively, are not included in the calculation of diluted EPS as their effect would be anti-dilutive. As of March 31, 2019 and September 30, 2018, the Company had 3,291,000 in stock options outstanding which are exercisable at the holders’ option, with an exercise price of $0.0067, which are not included in the calculation of diluted EPS as their effect would be anti-dilutive.
Recent Pronouncements	Recently Issued Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement In May 2014, the FASB issued ASU, 2014-09— Revenue from Contracts with Customers (Topic 606) In February 2016, the FASB issued ASU No. 2016-02, Leases, In April 2016, the FASB issued ASU 2016 – 10 “ Revenue from Contracts with Customers: identifying Performance Obligations and Licensing In August 2016, the FASB issued ASU 2016-15, “ Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments U In January 2017, FASB issued ASU 2017-01, “ Business Combinations (Topic 805) Clarifying the Definition of a Business On May 10, 2017, the Financial Accounting Standards Board (“FASB”) issued an Accounting Standards Update (“ASU”) 2017-09 “ Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	6 Months Ended
	Mar. 31, 2019
Employee
Schedule of share-based compensation, stock options, activity	The following is a summary of outstanding stock options issued to employees and directors as of March 31, 2019 and September 30, 2018: Number Exercise Price per Average Outstanding March 31, 2019 and September 30, 2018 2,916,000 $ 0.0067 4.95 Exercisable, March 31, 2019 and September 30, 2018 2,916,000 $ 0.0067 4.95
Non-Employee
Schedule of share-based compensation, stock options, activity	The following is a summary of outstanding stock options issued to non-employees, excluding directors, as of March 31, 2019 and September 30, 2018: Number Exercise Price per Average Outstanding March 31, 2019 and September 30, 2018 375,000 $ 0.0067 4.54 Exercisable, March 31, 2019 and September 30, 2018 375,000 $ 0.0067 4.54

NATURE OF OPERATIONS, BASIS O_3

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares	6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Sep. 30, 2018
Disclosure Nature Of Operations Basis Of Presentation And Summary Of Significant Accounting Policies Details Narrative Abstract
Anti-Dilutive Shares Excluded from Earning Per Share	334,050	317,009
Options outstanding	3,291,000		3,291,000

GOING CONCERN AND MANAGEMENT'_2

GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2019	Mar. 31, 2018	Sep. 30, 2018
Disclosure Going Concern And Managements Liquidity Plans Details Narrative Abstract
Accumulated deficit	$ (5,090,990)				$ (5,090,990)		$ (5,084,494)
Working captial deficiency	(227,588)				(227,588)
Net Income (Loss)	(3,637)	$ (2,859)	$ (9,389)	$ (7,629)	(6,496)	$ (17,018)
Cash used in operating activities					(1,683)	$ (21,549)
Cash	$ 587				$ 587		$ 2,270

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Sep. 30, 2018
Account Payable - Related Parties	$ 86,913		$ 86,913		$ 85,062
Related Party, General and Administrative Expenses	455	$ 4,229	1,253	$ 10,029
Entity Controller By Sole Officer and Director [Member]
Account Payable - Related Parties	$ 12,036		$ 12,036		$ 10,185

CONVERTIBLE NOTES PAYABLE AND_2

CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE (Details Narrative) - USD ($)	Mar. 31, 2019	Sep. 30, 2018	Apr. 02, 2018	Jan. 10, 2018	Mar. 30, 2017	Mar. 17, 2017
Convertible notes payable	$ 20,000	$ 20,000
Notes payable	43,000	43,000
Trius Holdings Limited [Member]
Convertible notes payable						$ 10,000
Accured Interest	2,441	1,810
Individual [Member]
Convertible notes payable					$ 10,000
Accured Interest	2,403	1,805
Mediapark Investments Limited [Member]
Accured Interest	3,365	2,684
Notes payable				$ 23,000
Individual [Member]
Accured Interest	$ 2,387	$ 1,190
Notes payable			$ 20,000

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - $ / shares	6 Months Ended	12 Months Ended
	Mar. 31, 2019	Sep. 30, 2018
Number of Options
Number of Options Outstanding, Beginning	3,291,000
Number of Options Outstanding, Ending	3,291,000	3,291,000
Employee
Number of Options
Number of Options Outstanding, Beginning	2,916,000
Number of Options Outstanding, Ending	2,916,000	2,916,000
Number of Options, Exercisable	2,916,000	2,916,000
Exercise Price per Share
Exercise Price per Share Outstanding, Beginning	$ 0.0067
Exercise Price per Share Outstanding, Ending	0.0067	$ 0.0067
Exercise Price per Share, Exercisable	$ 0.0067	$ 0.0067
Average Remaining Term (in Years)
Average Remaining Terms Outstanding, Ending	4 years 11 months 12 days	4 years 11 months 12 days
Average Remaining Terms, Exersiable	4 years 11 months 12 days	4 years 11 months 12 days
Non-Employee
Number of Options
Number of Options Outstanding, Beginning	375,000
Number of Options Outstanding, Ending	375,000	375,000
Number of Options, Exercisable	375,000	375,000
Exercise Price per Share
Exercise Price per Share Outstanding, Beginning	$ 0.0067
Exercise Price per Share Outstanding, Ending	0.0067	$ 0.0067
Exercise Price per Share, Exercisable	$ 0.0067	$ 0.0067
Average Remaining Term (in Years)
Average Remaining Terms Outstanding, Ending	4 years 6 months 14 days	4 years 6 months 14 days
Average Remaining Terms, Exersiable	4 years 6 months 14 days	4 years 6 months 14 days